Table 4. Subgroup analysis of plasma CZP concentration ([CZP]) at Week 24 (observed data) in HIKARI.
LDA |
|||||||
---|---|---|---|---|---|---|---|
Groups | [CZP] Subgroup no. | [CZP] (μg/mL) | N | %Group | [CZP] geometric mean (μg/mL) | N | %Subgroup |
LD (n = 103 a ) | 1 | <12.0 | 21 | 20.4 | 4.6 | 7 | 33.3 |
2 | ≤12.0, <26.6 | 27 | 26.2 | 19.2 | 9 | 33.3 | |
3 | ≤26.6, <38.1 | 32 | 31.1 | 31.8 | 12 | 37.5 | |
4 | ≤38.1 | 23 | 22.3 | 51.5 | 12 | 52.2 | |
No-LD (n = 87 a ) | 1 | <12.0 | 26 | 29.9 | 3.8 | 4 | 15.4 |
2 | ≤12.0, <26.6 | 21 | 24.1 | 19.2 | 7 | 33.3 | |
3 | ≤26.6, <38.1 | 15 | 17.2 | 31.4 | 2 | 13.3 | |
4 | ≤38.1 | 25 | 28.7 | 52.9 | 8 | 32.0 |
CZP-ADAb, antibodies to CZP; LD, loading dose; LDA, low disease activity.
Patients for whom data are available.